BWX Technologies, Inc. (NYSE:BWXT) Receives $222.96 Consensus PT from Brokerages

BWX Technologies, Inc. (NYSE:BWXT) has been assigned an average rating of “Moderate Buy” from the fifteen ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, eight have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $228.00.

Several analysts recently commented on BWXT shares. BTIG Research lifted their price objective on BWX Technologies from $225.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Deutsche Bank Aktiengesellschaft raised BWX Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $205.00 to $255.00 in a report on Friday, May 15th. Truist Financial lifted their price objective on BWX Technologies from $205.00 to $212.00 and gave the stock a “hold” rating in a report on Monday, May 11th. TD Securities started coverage on BWX Technologies in a report on Thursday, March 12th. They issued a “buy” rating and a $230.00 price objective for the company. Finally, TD Cowen started coverage on BWX Technologies in a report on Thursday, March 12th. They issued a “buy” rating and a $230.00 price objective for the company.

BWX Technologies Stock Performance

Shares of BWXT opened at $195.65 on Monday. The company has a debt-to-equity ratio of 1.58, a current ratio of 2.40 and a quick ratio of 2.33. BWX Technologies has a one year low of $123.12 and a one year high of $241.82. The firm has a market capitalization of $17.92 billion, a P/E ratio of 52.31, a PEG ratio of 3.23 and a beta of 0.73. The business has a fifty day moving average of $212.98 and a 200 day moving average of $199.61.

BWX Technologies (NYSE:BWXT) last issued its quarterly earnings data on Monday, May 4th. The technology company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.92 by $0.20. BWX Technologies had a return on equity of 31.33% and a net margin of 10.20%.The company had revenue of $860.22 million during the quarter, compared to analyst estimates of $837.47 million. During the same quarter in the previous year, the company posted $0.91 earnings per share. BWX Technologies’s revenue was up 26.1% compared to the same quarter last year. BWX Technologies has set its FY 2026 guidance at 4.600-4.750 EPS. As a group, sell-side analysts anticipate that BWX Technologies will post 4.71 EPS for the current year.

BWX Technologies Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Tuesday, May 19th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Tuesday, May 19th. BWX Technologies’s payout ratio is currently 28.88%.

Insider Activity

In other BWX Technologies news, CFO Michael Thomas Fitzgerald sold 2,417 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $209.25, for a total transaction of $505,757.25. Following the completion of the sale, the chief financial officer owned 6,884 shares of the company’s stock, valued at approximately $1,440,477. The trade was a 25.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Rex D. Geveden sold 10,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $204.81, for a total value of $2,048,100.00. Following the sale, the chief executive officer directly owned 202,491 shares of the company’s stock, valued at $41,472,181.71. This represents a 4.71% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.60% of the company’s stock.

Institutional Trading of BWX Technologies

Several hedge funds have recently bought and sold shares of BWXT. Goldman Sachs Group Inc. grew its holdings in BWX Technologies by 0.3% during the first quarter. Goldman Sachs Group Inc. now owns 141,680 shares of the technology company’s stock valued at $13,977,000 after purchasing an additional 371 shares during the period. Caxton Associates LLP bought a new stake in BWX Technologies during the first quarter valued at about $304,000. Flow Traders U.S. LLC bought a new stake in BWX Technologies during the second quarter valued at about $404,000. NewEdge Advisors LLC grew its holdings in BWX Technologies by 670.0% during the second quarter. NewEdge Advisors LLC now owns 7,030 shares of the technology company’s stock valued at $1,013,000 after purchasing an additional 6,117 shares during the period. Finally, Sei Investments Co. grew its holdings in BWX Technologies by 44.9% during the second quarter. Sei Investments Co. now owns 256,969 shares of the technology company’s stock valued at $37,018,000 after purchasing an additional 79,646 shares during the period. Institutional investors own 94.39% of the company’s stock.

BWX Technologies Company Profile

BWX Technologies, Inc (NYSE: BWXT) is a specialized supplier of nuclear components and services, primarily serving the U.S. government and commercial markets. The company’s core expertise lies in the design, fabrication and servicing of nuclear propulsion systems for the U.S. Navy, where it supports the maintenance and overhaul of naval nuclear reactors. In addition to defense applications, BWXT develops small modular reactors (SMRs), nuclear fuel and related technologies for non?defense power generation, offering scalable solutions to meet evolving energy and industrial demands.

Beyond propulsion and power systems, BWXT is a leading producer of medical radioisotopes used in diagnostic imaging and cancer treatment.